Thoughtful capital
for world-shaping healthtech founders.
An early-stage healthtech investment firm led by proven entrepreneurs, deeply embedded in Singapore, providing accelerated access to the U.S., empowering startups to compete globally.
ViSION
Establish relationships with founders and investors who share our unwavering commitment to ethical behaviour, consistently acting with integrity, respect,
and purpose.
Transformative
Investments
Deploy our capital with a perspective centered on diligence, expertise, and a fiduciary mindset to achieve outsized risk-adjusted returns.
Support outstanding founders with our team's decades of expertise and our unique operating model spanning Asia and the U.S.
TEAM
.png)
Ara Tavitian, MD
Paul Scibetta
Jonathan Bandel, MPA, MSF
.png)
Vartan Hovsepian
.png)
Louise Roman, JD
Yong Chern Chet, MB BCh, MRCSEd, MPS
James Best, MD, MBBS
ADVISOR, SINGAPORE HEALTH ECOSYSTEM & CLINICAL RESEARCH
.png)
Pinchas (Hassy) Cohen, MD, PhD
Advisor, Ageing & Digital Therapeutics
Eric Dworkin, MPA
Advisor, US Payors
Zsolt Kulcsar, DO, MPH, MBA
Advisor, Virtual Health and Project Scoping & Implementation
.png)
Gilbert S. Omenn, MD, PhD
Advisor, Precision Medicine
.png)
Tan Wee Theng
ADVISOR, ASIA ECOSYSTEM
VALUE CREATION CHAIN
ECOSYSTEM
commercialisation
GROWTH
INVESTMENT THEMES
Genomics and novel biomarkers that diagnose, track activity, and serve as targets for therapy.
Proactive risk management tools that tailor early interventions and optimise outcomes by supporting informed consumers.
Innovations that give people greater control over their health, including decentralised data ownership, portability, and interoperability in a secure manner.
Hardware and software platforms that enable remote monitoring for maintenance of wellness, disease prevention, and management at home.
Software as a Medical Device (SaMD), mobile apps, augmented and virtual reality, and other digital technologies as medicine that force a rethink of how we treat all types of disease, including behavioural health and neurodegenerative conditions.
Digital solutions backed by innovative technologies and business models that incent behavioural change leading to healthier outcomes and compliance with clinical care pathways.
Robotic and digital solutions that enable at-home rehab and assistance in activities of daily living.
Software that addresses loneliness and isolation.
Platforms that improve training and quality of life for caregivers, families, and patients.
Beliefs we must share for success
Singapore's robust innovation community is well-positioned to produce globally competitive healthtech startups due to their world-class research, cutting-edge technology, intense focus on talent development, and leading institutions. For example, Singapore is 2nd in World Bank's Ease of Doing Business Survey, has the 4th highest researcher FTEs per capita globally, has the 2nd most "best in world" category rankings in 2022 Global Innovation Index, and is the 1st country to achieve nationwide 5G coverage.
The U.S. market provides unparalleled growth opportunities for startups with the potential to change the future of health and care. The U.S. accounts for 43.5% of global health spend, 76% of unicorns created in healthtech, and $0.72 of every dollar invested in digital health. The U.S. has the infrastructure to support innovation, including 86% of health systems having one or more executives responsible for innovation.
A model deeply embedded in Singapore, underpinned by a team of expert healthcare operators in the U.S., designed to deliver alpha at every step of the process, and committed to investing efficiently at high concentrations in early stages to generate outsized returns.
For more information, contact us at:
info@22healthventures.com
